Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance

Objective. To investigate the effect of acarbose therapy on the long-term prognosis of patients with acute coronary syndromes (ACS) complicating newly diagnosed impaired glucose tolerance (IGT). Methodology. 135 patients hospitalized for ACS who had been newly diagnosed with IGT were randomly assign...

Full description

Saved in:
Bibliographic Details
Published in:Journal of diabetes research 2016-01, Vol.2016 (2016), p.1-5
Main Authors: Liu, Jing-cheng, Chen, Xue-jun, Du, Ai-ming, Yun, Peng, Xiao, Hu
Format: Article
Language:English
Subjects:
Acarbose - therapeutic use
Acute Coronary Syndrome - complications
Acute coronary syndromes
Aged
Angina pectoris
Blood pressure
Body mass index
Cardiovascular disease
Cardiovascular Diseases - diagnostic imaging
Cardiovascular Diseases - epidemiology
Carotid Arteries - diagnostic imaging
Carotid Intima-Media Thickness
Clinical Study
Coronary vessels
Diabetes
Female
Glucose
Glucose Intolerance - complications
Glucose Intolerance - diagnosis
Glucose Intolerance - drug therapy
Glycoside Hydrolase Inhibitors - therapeutic use
Health risk assessment
Heart attacks
Heart failure
Hormone replacement therapy
Humans
Hypertension
Incidence
Male
Medical prognosis
Middle Aged
Mortality
Prognosis
Statistical analysis
Stroke
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective. To investigate the effect of acarbose therapy on the long-term prognosis of patients with acute coronary syndromes (ACS) complicating newly diagnosed impaired glucose tolerance (IGT). Methodology. 135 patients hospitalized for ACS who had been newly diagnosed with IGT were randomly assigned to acarbose group (150 mg/day, n = 67 ) or control group (no acarbose, n = 68 ). All cases in each group were given the same elementary treatment. Mean follow-up was 2.3 years. The incidence of major adverse cardiovascular event (MACE) and carotid intima-middle thickness (CIMT) were statistically analyzed. Results. During the mean follow-up of 2.3 years, the risk of recurrent MACE in acarbose group was decreased significantly compared with that in control group (26.67% versus 46.88%, P < 0.05 ); at the same time, thickening of the CIMT was significantly slower than the control group ((1.28 ± 0.42) mm versus (1.51 ± 0.64) mm, P < 0.05 ). Conclusions. Acarbose can effectively reduce the risk of MACE in ACS patients with newly diagnosed IGT, simultaneously retarding the progression of carotid intima-media thickness.
ISSN:2314-6745
2314-6753
DOI:10.1155/2016/1602083